• Founded: 2021
  • Location: Waltham, MA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Autoimmune conditions
  • Drug types: IMM, ALL, ONC, INF, NEU
  • Lead product: Undisclosed
  • Product link:
  • Funding: $50M A Jun 2021; $17M A Feb 2021

job board

Short description:

Antibody Discovery Platform

Drug notes:

Additional undisclosed programs RD allergy, oncology, infectious diseases, neurology conditions

Long description:

ImmuneID is using high-throughput technology to understand individual immune responses. The human immune system plays an important role throughout the disease process. Using their proprietary platform, ImmuneID is profiling antibodies against various pathogens that can be analyzed from low volumes of various sample types. The platform uses next generation sequencing, robotic automation and AI to identify protective or biomarker epitopes that can be recognized by antibodies. As the platform is unbiased, works with various sample types and is high-throughout, it enables ImmuneID to look broadly across multiple therapeutic areas. This includes developing therapeutics for autoimmunity, severe allergy, oncology and infectious diseases.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy